No respite for RemeGen as problems and losses pile up
The developer of innovative drugs has sustained a series of blows to its finances, corporate partnerships, management team and star product, leaving investors jittery Key Takeaways: Despite rising revenue, RemeGen…
Junshi Biosciences Back in the Red, Pins Hopes on Covid Drugs
The innovative drug developer reported a first-quarter loss as a result of a steep drop in licensing revenue Key Takeaways: Junshi Biosciences’ revenue tumbled 61% in the first quarter, reflecting…
Recent Articles
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
